WO2000016760A3 - New use of prostaglandin e2 antagonists - Google Patents

New use of prostaglandin e2 antagonists Download PDF

Info

Publication number
WO2000016760A3
WO2000016760A3 PCT/JP1999/005152 JP9905152W WO0016760A3 WO 2000016760 A3 WO2000016760 A3 WO 2000016760A3 JP 9905152 W JP9905152 W JP 9905152W WO 0016760 A3 WO0016760 A3 WO 0016760A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostaglandin
antagonists
new use
receptor
activity
Prior art date
Application number
PCT/JP1999/005152
Other languages
French (fr)
Other versions
WO2000016760A2 (en
Inventor
Yutaka Kohno
Yoshiyuki Tenda
Shoko Nakazato
Original Assignee
Fujisawa Pharmaceutical Co
Yutaka Kohno
Yoshiyuki Tenda
Shoko Nakazato
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co, Yutaka Kohno, Yoshiyuki Tenda, Shoko Nakazato filed Critical Fujisawa Pharmaceutical Co
Priority to JP2000573721A priority Critical patent/JP2002526442A/en
Publication of WO2000016760A2 publication Critical patent/WO2000016760A2/en
Publication of WO2000016760A3 publication Critical patent/WO2000016760A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Prostaglandin E2 receptor blockets, particularly EP4 receptor blocker, have diuretic activity with a various characteristics such as a lower kaluretic activity relative to natriuretic effect, a larger phosphorus excretion, or the like. Therefore, they are useful for preparation of medicament indicated treating or preventing various edema, hypertension, premenstrual tension, urinary calculus, oliguria, hyperphosphaturia, or the like.
PCT/JP1999/005152 1998-09-23 1999-09-20 New use of prostaglandin e2 antagonists WO2000016760A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2000573721A JP2002526442A (en) 1998-09-23 1999-09-20 Novel use of prostaglandin E2 antagonist

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATPP6088 1998-09-23
AUPP6088A AUPP608898A0 (en) 1998-09-23 1998-09-23 New use of prostaglandin E2 antagonists

Publications (2)

Publication Number Publication Date
WO2000016760A2 WO2000016760A2 (en) 2000-03-30
WO2000016760A3 true WO2000016760A3 (en) 2000-06-08

Family

ID=3810304

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1999/005152 WO2000016760A2 (en) 1998-09-23 1999-09-20 New use of prostaglandin e2 antagonists

Country Status (3)

Country Link
JP (1) JP2002526442A (en)
AU (1) AUPP608898A0 (en)
WO (1) WO2000016760A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43372E1 (en) 1999-03-05 2012-05-08 Duke University C16 unsaturated FP-selective prostaglandins analogs
US8906962B2 (en) 2000-03-31 2014-12-09 Duke University Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US9346837B2 (en) 2000-03-31 2016-05-24 Duke University Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
NZ535748A (en) * 2002-04-12 2007-06-29 Pfizer Use of EP4 receptor ligands in the treatment of IL-6 involved diseases
US7414029B2 (en) 2002-05-23 2008-08-19 Theratechnologies, Inc. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
EP1878741A3 (en) * 2002-05-23 2008-02-20 Theratechnologies Inc. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
WO2004032867A2 (en) * 2002-10-09 2004-04-22 Tolerrx, Inc. Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use
ES2584606T3 (en) 2002-10-10 2016-09-28 Ono Pharmaceutical Co., Ltd. Microspheres comprising ONO-1301
WO2004073589A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep4 (prostaglandin e2 ep4)
JP2007516950A (en) * 2003-12-22 2007-06-28 アステラス製薬株式会社 Ornithine derivatives that are prostaglandin E2 agonists or antagonists
WO2006054536A1 (en) * 2004-11-16 2006-05-26 Nippon Shinyaku Co., Ltd. Therapeutic agent for urolithiasis
UY30121A1 (en) 2006-02-03 2007-08-31 Glaxo Group Ltd NEW COMPOUNDS
NZ577109A (en) 2006-12-15 2011-12-22 Glaxo Group Ltd Benzamide derivatives as ep4 receptor agonists
US9365485B2 (en) 2007-01-25 2016-06-14 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
AU2008208042B2 (en) 2007-01-25 2014-02-27 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
EP2417974A1 (en) 2007-02-28 2012-02-15 Schering Corporation Combination therapy for treatment of immune disorders
CA2639412A1 (en) 2007-09-11 2009-03-11 Universite Laval Prostaglandin e2 modulation and uses thereof
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
EP2392323A4 (en) 2009-01-30 2012-09-26 Univ Kyoto Prostate cancer progression inhibitor and progression inhibition method
PL2562160T3 (en) * 2010-03-31 2015-03-31 Toray Industries Therapeutic agent or preventive agent for urine collection disorder
CA2793709C (en) * 2010-03-31 2017-09-12 Toray Industries, Inc. Therapeutic agent or prophylactic agent for fibromyalgia
AU2013305633B2 (en) 2012-08-24 2018-03-08 Board Of Regents, The University Of Texas System Heterocyclic modulators of HIF activity for treatment of disease
EP2888256A4 (en) * 2012-08-24 2016-02-17 Univ Texas Heterocyclic modulators of hif activity for treatment of disease
JP6400479B2 (en) 2012-10-29 2018-10-03 株式会社カルディオ Lung disease specific therapeutic agent
WO2014194209A1 (en) 2013-05-31 2014-12-04 Allergan, Inc. Substituted cyclopentenes as therapeutic agents
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
DK3110420T3 (en) 2014-02-25 2019-05-13 Board Of Regents Univ Of Texas System SALT OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASES

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017393A1 (en) * 1993-12-20 1995-06-29 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryloxazole derivatives
WO1997003973A1 (en) * 1995-07-21 1997-02-06 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryl oxazole derivatives
WO1998055468A1 (en) * 1997-06-02 1998-12-10 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds useful as pge2 agonists and antagonists
WO1999021843A1 (en) * 1997-10-27 1999-05-06 Fujisawa Pharmaceutical Co., Ltd. 4, 5-diaryloxazole compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017393A1 (en) * 1993-12-20 1995-06-29 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryloxazole derivatives
WO1997003973A1 (en) * 1995-07-21 1997-02-06 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryl oxazole derivatives
WO1998055468A1 (en) * 1997-06-02 1998-12-10 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds useful as pge2 agonists and antagonists
WO1999021843A1 (en) * 1997-10-27 1999-05-06 Fujisawa Pharmaceutical Co., Ltd. 4, 5-diaryloxazole compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COLEMAN, ROBERT A. ET AL: "EP4-receptors and cyclic AMP in pig venous smooth muscle: evidence with agonists and the EP4-antagonist, AH22921", ADV. PROSTAGLANDIN, THROMBOXANE, LEUKOTRIENE RES. (1995), 23(PROSTAGLANDINS AND RELATED COMPOUNDS), 241-6, XP000884753 *
MAO G -F ET AL: "Prostaglandin E2 Both Stimulates and Inhibits Adenyl Cyclase on Platelets: Comparison of Effects on Cloned EP4 and EP3 Prostaglandin Receptor Subtypes", PROSTAGLANDINS,US,BUTTERWORTH, STONEHAM, MA, vol. 52, no. 3, 1 September 1996 (1996-09-01), pages 175 - 185, XP004070268, ISSN: 0090-6980 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43372E1 (en) 1999-03-05 2012-05-08 Duke University C16 unsaturated FP-selective prostaglandins analogs
US8906962B2 (en) 2000-03-31 2014-12-09 Duke University Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US9346837B2 (en) 2000-03-31 2016-05-24 Duke University Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US9579270B2 (en) 2000-03-31 2017-02-28 Duke University Compositions and methods for treating hair loss using non-naturally occurring prostaglandins

Also Published As

Publication number Publication date
WO2000016760A2 (en) 2000-03-30
JP2002526442A (en) 2002-08-20
AUPP608898A0 (en) 1998-10-15

Similar Documents

Publication Publication Date Title
WO2000016760A3 (en) New use of prostaglandin e2 antagonists
WO1999052493A3 (en) Compounds that inhibit the binding of integrins to their receptors
AU6877694A (en) Tricyclic benzazepine vasopressin antagonists
EA199700116A1 (en) TRICYCLIC BENZEZEPINS AS VAZOPRESSIN ANTAGONISTS, A METHOD OF THEIR RECEIVING, A PHARMOCOMPOSITION ON THEIR BASIS AND A METHOD OF TREATMENT
WO2001010842A3 (en) Melanocortin-4 receptor binding compounds and methods of use thereof
CA2293621A1 (en) 4-aminopyrrole(3,2-d) pyrimidines as neuropeptide y receptor antagonists
AU2711400A (en) Heteroaryl-aryl ureas as igf-1 receptor antagonists
EA199700117A1 (en) TRICYCLIC BENZE-GOLDEN ANTAGONISTS VAZOPRESSIN, METHOD FOR THEIR RECOVERY, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT OF MAMMALS USING Tricyclic Benzene
AUPQ105799A0 (en) Cell growth inhibition
WO2000027850A3 (en) Crf receptor antagonists and methods relating thereto
WO1998036061A3 (en) Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity
AU4531001A (en) Compounds with 5-HT<sub>1A</sub> activity useful for treating disorders of the outer retina
AU2541500A (en) Use of 3-(2,4,6-trimethylphenyl)- 4-neopentylcarbonyloxy- 5,5- tetr amethylene-delta3- dihydrofurane-2- on for controlling the white fly
WO2000044763A3 (en) Compositions for treating inflammatory response
WO2001007049A3 (en) Ophthalmic composition comprising ketotifen
DK0956033T3 (en) Total synthesis of the amino-Hip analog of didemnin A
WO1997010824A8 (en) Use of 5ht1b receptor antagonist for the treatment of vascular disease
CA2392804A1 (en) Combined agents for treatment of glaucoma
WO2002032901A3 (en) Bridged piperazine derivatives
CA2321658A1 (en) Disinfecting composition
ES2159683T3 (en) TRANSDERMIC FORMULATION OF A COMPOUND WITH MUSCARINIC ACTIVITY.
CA2213894A1 (en) Corrosion inhibiting composition
WO2004032840A3 (en) Compounds, compositions, and methods
DK0906100T3 (en) Use of 5-HT1A receptor antagonists to treat urinary incontinence
WO1998046632A3 (en) Inhibitors for urokinase receptor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 573721

Kind code of ref document: A

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase